Finoriq research workspace
Biohaven Ltd. (BHVN) SEC Filings & Filing Highlights
Biohaven Ltd. develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease. Review BHVN SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
- Company
- Biohaven Ltd. (BHVN)
- Ticker
- BHVN
- Market Cap
- $2.2B
- Latest Price
- $14.78
- Industry
- Biotech & Pharma
Biohaven Ltd. (BHVN) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Biohaven Ltd. (BHVN).
| Event | Form | Date |
|---|---|---|
| Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator,...Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Di... | 8-K7.01 | 2026-05-27 |
| Biohaven Ltd.: Corporate updateOn May 4, 2026, Biohaven Ltd. (the “Company”) entered into Amendment No. 2 (“Amendment No. 2”) to the Equity Distribution Agreement, dated... | 8-K8.01 | 2026-05-05 |
| Biohaven Reports Recent Business Developments and First Quarter 2026 Financial ResultsBiohaven Reports Recent Business Developments and First Quarter 2026 Financial Results | 8-K2.02 | 2026-05-04 |
| On April 28, 2026, Biohaven Ltd. held its 2026 annual meeting of shareholdersOn April 28, 2026, Biohaven Ltd. (the “Company”) held its 2026 annual meeting of shareholders (the “Annual Meeting”) | 8-K5.07 | 2026-05-04 |
| Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial R...Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results | 8-K2.02 | 2026-03-02 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.